RPN-002 embryo-implantation Phase 2
Nolasiban is an oral oxytocin-receptor antagonist being evaluated in an EU Phase 2 embryo-implantation study, EU CTN 2025-524896-22. Clinical pregnancy and live birth are different outcomes.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Private-company classification explicitly supported by ReproNovo’s October 5, 2026 announcement; recheck before activation.
- Research candidate, not a live market, clinical probability, company equity or access to private shares.
Primary evidence
EU Phase 2 readout — date unconfirmed
Company context
An official company source identifies the company as privately held. This is source-reported context, not independent legal-registry verification; recheck ownership, listing and acquisition status before any market listing.
Potential outcome market
Will ReproNovo publicly report the primary analysis of the designated RPN-002 embryo-implantation Phase 2 trial by the market deadline?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.